A Multiple Dose Study of LY3502970 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

April 4, 2022

Study Completion Date

April 4, 2022

Conditions

Healthy

Interventions

DRUG

LY3502970

Administered orally.

DRUG

Esomeprazole

Administered orally.

Trial Locations (1)

Quotient Clinical Ltd, Nottingham

All Listed Sponsors

collaborator

Quotient Sciences

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT05051566 - A Multiple Dose Study of LY3502970 in Healthy Participants | Biotech Hunter | Biotech Hunter